• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Pathog . Multidimensional analysis of immune cells from COVID-19 patients identified cell subsets associated with the severity at hospital admi

tetano

Editor, Senior Moderator
PLoS Pathog


. 2023 Jun 13;19(6):e1011432.
doi: 10.1371/journal.ppat.1011432. eCollection 2023 Jun. Multidimensional analysis of immune cells from COVID-19 patients identified cell subsets associated with the severity at hospital admission

Sergio Gil-Manso[SUP] 1 [/SUP], Diego Herrero-Quevedo[SUP] 2 [/SUP], Diego Carbonell[SUP] 3 4 [/SUP], Marta Martínez-Bonet[SUP] 5 [/SUP], Esther Bernaldo-de-Quirós[SUP] 5 [/SUP], Rebeca Kennedy-Batalla[SUP] 5 [/SUP], Jorge Gallego-Valle[SUP] 1 [/SUP], Rocío López-Esteban[SUP] 5 [/SUP], Elena Blázquez-López[SUP] 6 [/SUP], Iria Miguens-Blanco[SUP] 7 [/SUP], Rafael Correa-Rocha[SUP] 5 [/SUP], Vanessa Gomez-Verdejo[SUP] 2 [/SUP], Marjorie Pion[SUP] 1 [/SUP]



Affiliations
Abstract

Background: SARS-CoV-2 emerged as a new coronavirus causing COVID-19, and it has been responsible for more than 760 million cases and 6.8 million deaths worldwide until March 2023. Although infected individuals could be asymptomatic, other patients presented heterogeneity and a wide range of symptoms. Therefore, identifying those infected individuals and being able to classify them according to their expected severity could help target health efforts more effectively.
Methodology/principal findings: Therefore, we wanted to develop a machine learning model to predict those who will develop severe disease at the moment of hospital admission. We recruited 75 individuals and analysed innate and adaptive immune system subsets by flow cytometry. Also, we collected clinical and biochemical information. The objective of the study was to leverage machine learning techniques to identify clinical features associated with disease severity progression. Additionally, the study sought to elucidate the specific cellular subsets involved in the disease following the onset of symptoms. Among the several machine learning models tested, we found that the Elastic Net model was the better to predict the severity score according to a modified WHO classification. This model was able to predict the severity score of 72 out of 75 individuals. Besides, all the machine learning models revealed that CD38+ Treg and CD16+ CD56neg HLA-DR+ NK cells were highly correlated with the severity.
Conclusions/significance: The Elastic Net model could stratify the uninfected individuals and the COVID-19 patients from asymptomatic to severe COVID-19 patients. On the other hand, these cellular subsets presented here could help to understand better the induction and progression of the symptoms in COVID-19 individuals.


 
Back
Top Bottom